Elevated cerebrospinal fluid beta-2 microglobulin as a tumor marker in a patient with myeloma of the central nervous system

Authors

• Enaam M. Alsobhi, Consultant Hematologist, King Khalid National Guard Hospital, PO Box 9515, Jeddah 21423, Kingdom of Saudi Arabia. Tel. +966 (2) 6240000. Fax. +966 (2) 6240000 Ext. 1240. E-mail: ensobhi{at}hotmail.com
• Ibrahim A. Hashim, Department of Pathology, University of Texas Southwestern Medical Center, Dallas, United States of America.
• Mohammad A. Abdelaal, Departments of Pathology and Laboratory Medicine, King Khalid National Guard Hospital, Jeddah, Kingdom of Saudi Arabia.
• Ahmad M. Aljifri, Departments of Pathology and Laboratory Medicine, King Khalid National Guard Hospital, Jeddah, Kingdom of Saudi Arabia.
• Abdelrahman M. Alshamy, Department of Medical Imaging, King Khalid National Guard Hospital, Jeddah, Kingdom of Saudi Arabia.

Abstract

Myeloma involvement of the nervous system is rare. Extensive literature review revealed only a few cases reported from different parts of the world. The presence of CNS symptoms and detection of plasma cells in the CSF is the usual basis of diagnosis. In addition, immunoelectrophoresis and immunofixation for detection of monoclonal protein confirm the diagnosis in some cases, while some authors used flow cytometry and cytogenetic studies on CSF. Reports of multiple myeloma also include unfavorable cytogenetic abnormalities of chromosome 13. We report a case with relapsed CNS multiple myeloma with the detection of elevated beta-2 microglobulin (beta2M) as a tumor marker in the CSF.

Article Type

Case Report

First Page

128

Last Page

130

Recommended Citation

Alsobhi, Enaam M.; Hashim, Ibrahim A.; Abdelaal, Mohammad A.; Aljifri, Ahmad M.; and Alshamy, Abdelrahman M. (2007) "Elevated cerebrospinal fluid beta-2 microglobulin as a tumor marker in a patient with myeloma of the central nervous system," Saudi Medical Journal: Vol. 28: Iss. 1, Article 24.
DOI: https://doi.org/10.15537/1658-3175.3753